Join the Wegovy group to help and get support from people like you.
Wegovy News
GLP-1 Meds May Help Extremely Obese Qualify for Weight-Loss Surgery
FRIDAY, June 14, 2024 – Taking a cutting-edge weight-loss drug could help extremely obese patients drop enough pounds to be eligible for bariatric surgery, a new study shows. Patients with extreme...
GLP-1 RA Use Linked to Lower Quality of Bowel Preparation
THURSDAY, June 13, 2024 – The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for diabetes or obesity is associated with a lower quality of bowel preparation among patients undergoing...
Patients Can Take GLP-1 RA Medications Before Surgery
WEDNESDAY, June 12, 2024 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications do slow gastric emptying but not by enough to warrant discontinuing medications before surgery, according...
Taking a GLP-1 Medicine? Here's What Experts Say You Should Eat
TUESDAY, June 11, 2024 – Folks using a weight-loss drugs like Ozempic, Wegovy or Zepbound still have nutritional requirements for good health, even if they’re eating less. A new set of nutritional r...
Greater Reduction Seen in Mortality With Bariatric Surgery Than GLP-1 RAs
MONDAY, June 10, 2024 – Bariatric metabolic surgery (BMS) is associated with a greater reduction in mortality than glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment among adults with a...
It's Safe to Take GLP-1 Weight Loss Meds Before Surgery: Study
THURSDAY, June 6, 2024 – Despite recent concerns that taking Ozempic, Wegovy or other GLP-1 medications might be unsafe before a surgery, a new review has uncovered no such danger. The issue arose...
Wegovy, Ozempic May Help Curb Alcohol Dependence
TUESDAY, June 4, 2024 – Could the blockbuster GLP-1 meds like Wegovy and Ozempic have a role to play in helping people cut down on problem drinking? A new study suggests so. Researchers at Case...
GLP-1 Weight Loss Meds Might Keep Your Pancreas Healthy
MONDAY, June 3, 2024 – Ozempic and Wegovy might help lower the risk of pancreatitis in patients with obesity and type 2 diabetes, a new study says. Up to now, doctors have been cautious about...
Could New Weight-Loss Drugs Be Changing Women's Taste for Sweets?
MONDAY, June 3, 2024 – Ozempic and Wegovy appear to improve people’s sensitivity to tastes, potentially lowering their desire for sweets, a new study suggests. The active ingredient in the w...
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 – For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from cardiovascular causes,...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 – Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease, according to a study...
Costs, Side Effects Drive Folks to Quit New Weight-Loss Meds
THURSDAY, May 23, 2024 – Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than...
Use of GLP-1 Meds Have Risen 7-Fold Among Young Americans
WEDNESDAY, May 22, 2024 – The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 – For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research letter published...
'Hungry Gut' Gene Test Shows Who'll Benefit Most From Wegovy
TUESDAY, May 21, 2024 – You've watched others shed pounds in a matter of weeks after taking one of the new blockbuster weight-loss drugs, so you decide to try one of the medications yourself, only...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction